Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin AmyloidosisDavid Adams, Ole B. Suhr, Ivailo Tournev et al.|New England Journal of Medicine|2018Cited by 2.9k
Inotersen Treatment for Patients with Hereditary Transthyretin AmyloidosisMerrill D. Benson, Teresa Coelho, Márcia Waddington‐Cruz et al.|New England Journal of Medicine|2018Cited by 1.4k
Lipid Peroxidation Inhibition Blunts Nuclear Factor-κB Activation, Reduces Skeletal Muscle Degeneration, and Enhances Muscle Function in mdx MiceSonia Messina, Giuseppe Vita|American Journal Of Pathology|2006Cited by 115